Earnings History Data for Acorda Therapeutics, Inc. (ACOR) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA? (dalfampridine) Extended Release Tablets, 10 mg.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13-11-2023 | AH | ACOR | Acorda Therapeutics, Inc. | 12.07 | -7.16 | 0.00 | -11.40 | Acorda Therapeutics GAAP EPS of -$7.16, revenue of $27.72M [11/13/2023 4:04 PM] |
9.91 | 0.34 (3.55%) |
0.0 | 0.0 (0.00%) |
8.98 - 24.20 | 7,766 | 0 | 0 | ||
| 08-08-2023 | AH | ACOR | Acorda Therapeutics, Inc. | 18.69 | -7.55 | 0.00 | -55.60 | Acorda Therapeutics GAAP EPS of -$7.55, revenue of $29.68M [8/8/2023 4:41 PM] |
16.92 | 0.42 (2.55%) |
16.00 | -0.50 (-3.03%) |
5.22 - 24.80 | 6,776 | 10,000 | 1,859 | ||
| 11-05-2023 | AH | 4:00 PM ET (May 11) |
ACOR | Acorda Therapeutics, Inc. | 21.42 | -0.69 | 0.00 | -1.93 | Acorda Therapeutics GAAP EPS of -$0.69 beats by $0.42, revenue of $22.25M misses by $8.76M [5/11/2023 4:02 PM] |
0.6922 | -0.15 (-17.59%) |
0.86 | 0.02 (1.89%) |
0.26 - 1.24 | 901,079 | 4,630,000 | 109,360 | |
| 09-03-2023 | PM | Before the open (Mar 9) |
ACOR | Acorda Therapeutics, Inc. | 22.63 | 0.57 | 0.00 | -1.73 | Acorda Therapeutics GAAP EPS of $0.57, revenue of $31.47M [3/9/2023 7:01 AM] |
0.7850 | -0.22 (-21.50%) |
1.05 | 0.05 (5.00%) |
0.26 - 2.29 | 594,622 | 110,000 | 106,049 | |
| 01-11-2022 | AH | 4:00 PM ET (Nov 1) |
ACOR | Acorda Therapeutics, Inc. | 15.94 | -0.57 | -0.10 | -2.43 | Acorda Therapeutics GAAP EPS of -$0.57, revenue of $33.51M [11/1/2022 4:14 PM] |
0.7132 | -0.09 (-10.86%) |
0.72 | -0.08 (-10.47%) |
0.26 - 4.28 | 1,537,608 | 0 | 255,838 | |
| 04-08-2022 | AH | 4:00 PM ET (Aug 4) |
ACOR | Acorda Therapeutics, Inc. | 10.91 | -2.78 | -0.36 | -2.29 | Acorda Therapeutics Non-GAAP EPS of -$3.15, revenue of $31.05M [8/4/2022 4:06 PM] |
0.4450 | -0.08 (-15.24%) |
0.42 | -0.10 (-20.00%) |
0.28 - 4.99 | 600,596 | 250,000 | 92,969 | |
| 11-05-2022 | AH | 4:00 PM ET (May 11) |
ACOR | Acorda Therapeutics, Inc. | 11.29 | -1.93 | 0.00 | -3.53 | Acorda Therapeutics Non-GAAP EPS of -$1.66, revenue of $22.53M [5/11/2022 4:03 PM] |
0.6476 | -0.09 (-11.89%) |
0.78 | 0.05 (6.31%) |
0.63 - 6.36 | 198,315 | 90,000 | 263 | |
|
||||||||||||||||||
| 09-03-2022 | AH | 4:00 PM ET (Mar 9) |
ACOR | Acorda Therapeutics, Inc. | 24.53 | -1.73 | 0.00 | 9.82 | Acorda Therapeutics Non-GAAP EPS of -$0.67, revenue of $36.07M beats by $5.06M [3/9/2022 4:03 PM] |
1.81 | -0.44 (-19.39%) |
2.07 | -0.18 (-8.00%) |
1.61 - 6.36 | 102,230 | 50,000 | 1,962 | |
| 05-08-2021 | AH | 4:00 PM ET (Aug 5) |
ACOR | Acorda Therapeutics, Inc. | 43.05 | -2.29 | -2.09 | -2.22 | Acorda Therapeutics EPS misses by $0.20, beats on revenue [8/5/2021 4:06 PM] |
3.63 | -0.47 (-11.51%) |
3.77 | -0.33 (-8.05%) |
2.53 - 9.84 | 719,399 | 5,700,000 | 35,900 | |
| 06-05-2021 | AH | 4:00 PM ET (May 6) |
ACOR | Acorda Therapeutics, Inc. | 46.88 | -3.53 | -3.71 | -0.84 | Acorda Therapeutics EPS beats by $0.08, beats on revenue [5/6/2021 4:04 PM] |
4.64 | -0.07 (-1.49%) |
4.71 | 0.0 (0.00%) |
2.53 - 9.84 | 160,781 | 150,000 | 484 | |
| 04-03-2021 | AH | 4:00 PM ET (Mar 4) |
ACOR | Acorda Therapeutics, Inc. | 58.70 | 9.82 | -2.57 | -1.20 | Acorda Therapeutics EPS misses by $1.02, beats on revenue [3/4/2021 4:05 PM] |
5.21 | -1.57 (-23.16%) |
5.96 | -0.82 (-12.09%) |
2.53 - 9.84 | 985,931 | 268,009 | 13,766 | |
| 03-11-2020 | AH | 4:00 PM ET (Nov 3) |
ACOR | Acorda Therapeutics, Inc. | 41.93 | 0.30 | -0.47 | -0.52 | Acorda Therapeutics EPS beats by $0.10, beats on revenue [11/3/2020 4:05 PM] |
0.92 | -0.16 (-14.81%) |
0.9995 | -0.08 (-7.45%) |
0.42 - 2.78 | 4,644,890 | 4,711,463 | 266,080 | |
|
|
||||||||||||||||||
| 04-08-2020 | AH | 4:00 PM ET (Aug 4) |
ACOR | Acorda Therapeutics, Inc. | 30.17 | -2.22 | -0.64 | -0.65 | Acorda Therapeutics EPS beats by $0.05, beats on revenue [8/4/2020 4:07 PM] |
0.7078 | 0.07 (10.59%) |
0.73 | 0.09 (14.06%) |
0.60 - 4.46 | 2,993,250 | 3,194,165 | 761,284 | |
|
|
||||||||||||||||||
| 05-05-2020 | AH | 4:00 PM ET (May 5) |
ACOR | Acorda Therapeutics, Inc. | 42.82 | -0.84 | -0.56 | -0.62 | Acorda Therapeutics EPS misses by $0.10, misses on revenue [5/5/2020 4:02 PM] |
0.94 | 0.04 (4.44%) |
0.90 | -0.04 (-4.26%) |
0.70 - 12.15 | 2,171,829 | 1,492,042 | 5,661 | |
|
|
||||||||||||||||||